Binding of Glycans to the SARS CoV-2 Spike Protein, an Open Question: NMR Data on Binding Site Localization, Affinity, and Selectivity

Thorben Maass, George Ssebyatika, Marlene Brückner, Lea Breckwoldt, Thomas Krey, Alvaro Mallagaray, Thomas Peters*, Martin Frank, Robert Creutznacher

*Korrespondierende/r Autor/-in für diese Arbeit
1 Zitat (Scopus)

Abstract

We have used NMR experiments to explore the binding of selected glycans and glycomimetics to the SARS CoV-2 spike glycoprotein (S-protein) and to its receptor binding domain (RBD). STD NMR experiments confirm the binding of sialoglycans to the S-protein of the prototypic Wuhan strain virus and yield dissociation constants in the millimolar range. The absence of STD effects for sialoglycans in the presence of the Omicron/BA.1 S-protein reflects a loss of binding as a result of S-protein evolution. Likewise, no STD effects are observed for the deletion mutant Δ143–145 of the Wuhan S-protein, thus supporting localization of the binding site in the N-terminal domain (NTD). The glycomimetics Oseltamivir and Zanamivir bind weakly to the S-protein of both virus strains. Binding of blood group antigens to the Wuhan S-protein cannot be confirmed by STD NMR. Using 1H,15N TROSY HSQC-based chemical shift perturbation (CSP) experiments, we excluded binding of any of the ligands studied to the RBD of the Wuhan S-protein. Our results put reported data on glycan binding into perspective and shed new light on the potential role of glycan-binding to the S-protein.

OriginalspracheEnglisch
Aufsatznummere202202614
ZeitschriftChemistry - A European Journal
Jahrgang28
Ausgabenummer71
ISSN0947-6539
DOIs
PublikationsstatusVeröffentlicht - 20.12.2022

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)
  • Zentren: Zentrum für Medizinische Struktur- und Zellbiologie (ZMSZ)

DFG-Fachsystematik

  • 204-04 Virologie
  • 204-05 Immunologie

Coronavirus-Bezug

  • Forschung zu SARS-CoV-2 / COVID-19

Zitieren